Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

MEVPRO-2 (NCT06629779) is a global, randomized, double-blind, placebo‑controlled phase III trial in ARPI-naïve mCRPC patients. The key inclusion and exclusion criteria are detailed in the table below.

At a median follow-up of 60.7 months, patients in the combination arm of enzalutamide + leuprolide had significantly superior 5-year metastasis free survival rates (87.3% versus 71.4%; HR: 0.42, 95% ...